Trendlines Group Ltd. · SGX:42T
Trendlines — The Trendlines Group — Shareholder Meeting (April 2017)
22 slides from Trendlines's shareholder meeting presentation, Apr 26, 2017
Slide 1: Creating & Developing Companies To Improve the Human Condition
Creating & Developing Companies To Improve the Human Condition Steve Rhodes SGX: 42T Chairman and CEO OTCQX: TRNLY Todd Dollinger Chairman and CEO AGM 26 April 2017 Suntec Centre Singapore 1
Slide 2: Legal Disclaimer
Legal Disclaimer IMPORTANT NOTICE This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfo
Slide 3: I. About Trendlines
I. About Trendlines 3
Slide 4: Trendlines: Building Companies, Commercializing Innovation
Trendlines: Building Companies, Commercializing Innovation Life Science Incubators Invest in companies to improve the human condition In-House Innovation Center Invents and develops technologies to address unmet market needs 4
Slide 5: Trendlines Model: Creating a Foundation with Intensive Support
Trendlines Model: Creating a Foundation with Intensive Support Business Development Financial Potential customers, Consulting partners, investors Raising Capital Market Research Overheads Marketing Communications Bookkeeping, accounting, legal, operations Facilities & Infrastructure Technology Consu
Slide 6: Key Corporate Developments of FY2016
Key Corporate Developments of FY2016 • A stronger Trendlines • 8-year renewal of incubator license by Israeli government • Trendlines Medical Singapore established – S$2.2 million grant given (1/17) by Singaporean government • Growing partnerships and collaboration with major multinationals • B. Bra
Slide 7: Active Global Program to Raise Investor Awareness
Active Global Program to Raise Investor Awareness Investor Relations Activities 2016 • 75+ personal investor meetings • 20+ presentations to groups of investors • 20+ meetings with analysts • Weekly visits in Israel to Trendlines HQ & to portfolio companies by individual investors & investor groups
Slide 8: II. Financial Highlights
II. Financial Highlights 8
Slide 9: Financial Highlights: FY2016
Financial Highlights: FY2016 • Total current assets: US$17.3 million (FY2015: US$24.0 million) • Net portfolio value: US$83.7 million (FY2015: US$84.4 million) • Total equity: US$78.2 million (FY2015: US$84.2 million) • Total income: US$0.1 million (FY2015: US$9.9 million), includes: • US$8.0 millio
Slide 10: Key Components of Value (US$ million)
Key Components of Value (US$ million) Change in portfolio value during the year Balance sheet 1.1 (4.4) 5.4 (11.3) (6.0) 6.6 16.2 (12.5) (0.6) (0.9) 84.4 83.7 78.2 Net Portfolio Investment in FV Increase FV Decrease Book Value Dividends Net Portfolio Cash and Investment Non-recourse Deferred Deferre
Slide 11: III. Building our Portfolio
III. Building our Portfolio 11
Slide 12: Value Creation through Portfolio Expansion
Value Creation through Portfolio Expansion (US$ millions) 110 Portfolio Value with Exit Proceeds (as at 31 December) 100 90 80 70 60 50 40 2012 2013 2014 2015 2016 Including the fair value of investments in companies accounted for under the equity method. Portfolio Value cumulative exit proceeds Tre
Slide 13: A Strong Portfolio Primed for Success
A Strong Portfolio Primed for Success 43 portfolio companies 15 revenue-stage companies One of our 10 most valuable portfolio As at 31 December 2016; 25 written-off portfolio companies and 2 companies established companies as at 31 December 2016. before September 2007 not listed. 13
Slide 14: Building our Portfolio: Follow-on Funding
Building our Portfolio: Follow-on Funding 17 companies raised follow-on funding Advanced MemTech Ltd. Hargol FoodTech Ltd. ApiFix Ltd. Leviticus Cardio Ltd. Arcuro Medical Ltd. Liola Ltd. BioFishency Ltd. MiRobot Ltd. BioSight Ltd. Magdent Ltd. EdenShield Ltd. ProArc Medical Ltd. Fidmi Medical Ltd.
Slide 15: New Portfolio Companies 2016
New Portfolio Companies 2016 10 New Portfolio Companies Trendlines Medical: Trendlines Agtech: CorAlert AquiNovo Ceretrieve Hargol FoodTech liberDi InPlant Technologies OB Smart MetoMotion ZygoFix Seger Surgical 15
Slide 16: IV. Featured Company Leviticus Cardio
IV. Featured Company Leviticus Cardio 16
Slide 17: A Breakthrough in Heart Pump Technology
Trendlines’ Portfolio Company: A Breakthrough in Heart Pump Technology • People with end-stage heart failure usually die within six months. • Mechanical heart pumps keep them alive longer. © Can Stock Photo Inc./JFsPic The problem with mechanical heart pumps is the driveline that exits the body. 17
Slide 18: Leviticus Cardio: Making It Wireless
Leviticus Cardio: Making It Wireless • No cable • Recharge implanted battery – wirelessly • Freedom from external apparatus for 6-10 hours Achievements • Fully operational system • ISO 13485 • Key opinion leaders on board • 8 patents granted • Successful animal trials • High visibility among LVAD pl
Slide 19: Leviticus Cardio: LVADs Are an Under-Penetrated Market
Leviticus Cardio: LVADs Are an Under-Penetrated Market • Current LVAD market ~US$1 billion • Only ~10% market penetration attributed primarily to driveline issues 69,000 138,000 7,000 existing potential implants Leviticus Cardio’s wireless solution is the candidates candidates groundbreaking breakth
Slide 20: To Know Our Companies Is To Know Trendlines
To Know Our Companies Is To Know Trendlines Company Showcase 2017 20
Slide 21: BioFishency: Water Treatment for Efficient Aquaculture
BioFishency: Water Treatment for Efficient Aquaculture See the BioFishency presentation at the Trendlines 7th Annual Company Showcase. https://youtu.be/NF-fx7m35CE 21
Slide 22: Escala Medical: The First Non-Surgical Prolapse Repair Solution
Escala Medical: The First Non-Surgical Prolapse Repair Solution See the Escala Medical presentation at the Trendlines 7th Annual Company Showcase. https://youtu.be/RlbSdja1Zl0 22
The Trendlines Group — Shareholder Meeting (April 2017) on 6ix